Starboard Ditches Effort To Derail Bristol-Myers' $74B Buy
Activist hedge fund Starboard on Friday backed away from its campaign to upend Bristol-Myers Squibb's anticipated $74 billion Celgene takeover, hours after two proxy advisory firms came out in support of...To view the full article, register now.
Already a subscriber? Click here to view full article